FinscoFinsco

Bright Minds Biosciences (US.DRUG)

Capital Allocation Audit · Period: 2020 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.DRUG · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion100.0%→
ROE-5.8%↓
Cash Conversion-→
D/E Ratio0.00↑
Gross Margin-→
US.DRUG (Bright Minds Biosciences) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE               -5.8%    ↓
Cash Conversion       -    →
D/E Ratio          0.00    ↑
Gross Margin          -    →
Key Metrics
US.DRUG (Bright Minds Biosciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE -5.8% ↓
Cash Conversion - →
D/E Ratio 0.00 ↑
Gross Margin - →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies